Search

Your search keyword '"Schiltz, Gary E."' showing total 157 results

Search Constraints

Start Over You searched for: Author "Schiltz, Gary E." Remove constraint Author: "Schiltz, Gary E."
157 results on '"Schiltz, Gary E."'

Search Results

1. DART.2: bidirectional synaptic pharmacology with thousandfold cellular specificity

2. Age-stratified comorbid and pharmacologic analysis of patients with glioblastoma

3. Protein Structure Inspired Discovery of a Novel Inducer of Anoikis in Human Melanoma.

4. Protein Structure Inspired Drug Discovery

6. Targeting pleckstrin-2/Akt signaling reduces proliferation in myeloproliferative neoplasm models

7. Supplementary Data T1 from Advanced Age in Humans and Mouse Models of Glioblastoma Show Decreased Survival from Extratumoral Influence

8. Advanced age in humans and mouse models of glioblastoma show decreased survival from extratumoral influence

9. Chemokine receptor CXCR7 activates Aurora Kinase A and promotes neuroendocrine prostate cancer growth

13. Supplementary Methods and Supplementar Figures S1-S13 from Small Molecules Target the Interaction between Tissue Transglutaminase and Fibronectin

16. Targeting pleckstrin-2-Akt signaling reduces proliferation in myeloproliferative neoplasm models

19. Identification and Characterization of a Novel Indoleamine 2,3-Dioxygenase 1 Protein Degrader for Glioblastoma

20. Thousandfold Cell-Specific Pharmacology of Neurotransmission

21. Effects of Small Molecule Ligands on ACKR3 Receptors

26. Identification and Characterization of a Novel Brain-Penetrant Indoleamine 2,3 Dioxygenase 1 Protein Degrader for Glioblastoma

27. Tumor Cell IDO Enhances Immune Suppression and Decreases Survival Independent of Tryptophan Metabolism in Glioblastoma

28. Medicinal chemistry approaches to target the MNK–eIF4E axis in cancer

31. Heterologous Expression of the Unusual Terreazepine Biosynthetic Gene Cluster Reveals a Promising Approach for Identifying New Chemical Scaffolds

32. Immunosuppressive IDO in Cancer: Mechanisms of Action, Animal Models, and Targeting Strategies

34. Small-Molecule MYC Inhibitors Suppress Tumor Growth and Enhance Immunotherapy

35. A novel strategy to block mitotic progression for targeted therapy

43. Regulation of MLL/COMPASS stability through its proteolytic cleavage by taspase1 as a possible approach for clinical therapy of leukemia

44. Targeting Processive Transcription Elongation via SEC Disruption for MYC-Induced Cancer Therapy

46. Cancer-Associated IDH1 Promotes Growth and Resistance to Targeted Therapies in the Absence of Mutation

47. Palladium-Catalyzed Coupling Reactions on Functionalized 2-Trifluoromethyl-4-chromenone Scaffolds: Synthesis of Highly Functionalized Trifluoromethyl Heterocycles.

Catalog

Books, media, physical & digital resources